Ionis Pharmaceuticals
Healthcare & Life Sci
Company overview
Ionis Pharmaceuticals makes medicines that target RNA and DNA to treat genetic diseases. Its product Spinraza treats spinal muscular atrophy, a disease that weakens muscles. Tegsedi treats a hereditary form of amyloidosis, and Waylivra treats a rare fat-processing disorder called familial chylomicronemia syndrome. Qalsody treats a form of ALS linked to the SOD1 gene. The company is based in Carlsbad, California.
Ionis was founded in 1989 by Stanley T. Crooke under the name ISIS Pharmaceuticals. It changed its name to Ionis in December 2015. In 2024, the company had 1,069 employees and generated revenue of $705.1 million. It is publicly traded on NASDAQ under the ticker IONS. That is a small company by headcount, but its medicines treat rare diseases that affect small numbers of patients worldwide. Historically, the median salary is ~$150,000. Ionis Pharmaceuticals is an H-1B sponsor.
- Industry
- Healthcare & Life Sci
- Headquarters
- carlsbad, United States